Cardio-Cerebrovascular Protective Effects of Valsartan in High-Risk Hypertensive Patients With Coronary Artery Disease (from the Kyoto Heart Study)

被引:14
|
作者
Shiraishi, Jun [1 ]
Sawada, Takahisa [2 ]
Koide, Masahiro [2 ]
Yamada, Hiroyuki [2 ]
Matsubara, Hiroaki [2 ]
机构
[1] Kyoto First Red Cross Hosp, Dept Cardiol, Kyoto, Japan
[2] Kyoto Prefectural Univ, Sch Med, Dept Cardiovasc Med, Kyoto 606, Japan
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2012年 / 109卷 / 09期
关键词
CASE-J TRIAL; CARDIOVASCULAR EVENTS; SUBANALYSIS; MORBIDITY; MORTALITY; RAMIPRIL;
D O I
10.1016/j.amjcard.2011.12.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective was to examine whether previous coronary artery disease (CAD) influences the add-on effects of the angiotensin II receptor blocker (ARB) valsartan on cardio-cerebrovascular morbidity and mortality in high-risk hypertensive patients who participated in the Kyoto Heart Study. The primary end point was the same as in the main study: a composite of new-onset and/or worsening of cardiovascular and cerebrovascular events. Median follow-up was 3.27 years. According to the presence of previous CAD at baseline, the study population was divided into 2 groups (with CAD, n = 707; without CAD, n = 2,324) in which primary end-point events occurred more frequently in patients with CAD than in patients without CAD (15.1% vs 5.6%, hazard ratio [HR] 2.68, 95% confidence interval [CI] 2.11 to 3.42). Add-on valsartan significantly decreased the occurrence of the primary end-point events in patients with CAD (11.3% vs 19.0%, HR 0.59, 95% CI 0.41 to 0.85) and without CAD (3.7% vs 7.6%, HR 0.49, 95% CI 0.34 to 0.70) compared to non-ARB treatment. In the presence of previous CAD, patients with valsartan add-on treatment had a significantly lower prevalence of angina pectoris and stroke than those with non-ARB treatment, whereas the valsartan add-on effects on angina and stroke were not significant in the absence of CAD. Changes in blood pressure during the follow-up period did not differ significantly between study subgroups. In conclusion, in the presence or absence of previous CAD, valsartan add-on treatment prevented more cardio-cerebrovascular events than conventional non-ARB treatment in high-risk hypertensive patients. In addition, valsartan add-on treatment conferred not only an antianginal effect but also stroke prevention exclusively in hypertensive patients with CAD compared to those without CAD. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;109:1308-1314)
引用
收藏
页码:1308 / 1314
页数:7
相关论文
共 50 条
  • [31] A STUDY OF HIGH-RISK FACTORS FOR CORONARY-ARTERY DISEASE IN THE CHINESE
    HO, CH
    WANG, SP
    JAP, TS
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 800 - 800
  • [32] Combination Effect of Calcium Channel Blocker and Valsartan on Cardiovascular Event Prevention in Patients with High-Risk Hypertension: Ancillary Results of the KYOTO HEART Study
    Sawada, Takahisa
    Yamada, Hiroyuki
    Shiraishi, Jun
    Kimura, Shinzo
    Matsubara, Hiroaki
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2012, 34 (02) : 153 - 159
  • [33] Effects of Valsartan on morbidity and mortality of cardiovascular events in new-onset Diabetes Mellitus patients with high-risk hypertension: a sub-analysis of the KYOTO HEART Study
    Kimura, S.
    Sawada, T.
    Shiraishi, J.
    Yamada, H.
    Matsubara, H.
    EUROPEAN HEART JOURNAL, 2010, 31 : 800 - 800
  • [34] Biomarkers for identification of high-risk coronary plaques in patients with suspected coronary artery disease
    Pedersen, G. P.
    Dahl, J. D.
    Rasmussen, L. D. R.
    Blavnsfeldt, A. B.
    Boettcher, S. B.
    Boettcher, M. B.
    Nyegaard, M. N.
    Nissen, L. N.
    Winther, S. W.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [35] Risk factors that discriminate 'high-risk' from 'low-risk' Japanese patients with coronary artery disease
    Miwa, K
    Nakagawa, K
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 2000, 64 (11): : 825 - 830
  • [36] Awareness of coronary artery disease risk factors and homocysteine treatment in high-risk patients
    Salo, D
    Lavery, RF
    Olesnicky, N
    Milano, M
    ANNALS OF EMERGENCY MEDICINE, 2003, 42 (04) : S37 - S38
  • [37] Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study (Retraction of vol 30, pg 2461, 2009)
    Sawada, Takahisa
    Yamada, Hiroyuki
    Dahlof, Bjorn
    Matsubara, Hiroaki
    EUROPEAN HEART JOURNAL, 2013, 34 (14) : 1023 - 1023
  • [38] ATHEROSCLEROSIS RISK FACTORS, INFLAMMATION AND DENTAL STATE IN PATIENTS WITH CARDIO-CEREBROVASCULAR DISEASE AND EXCESSIVE OBESITY (BMI OVER 40) FROM ROMANIA
    Gutiu, I. A.
    Gutiu, L. I.
    Radulescu, F. S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 90 - 90
  • [39] SILENT EXERTIONAL ISCHEMIA IN PATIENTS WITH HIGH-RISK CORONARY-ARTERY DISEASE
    REISMAN, S
    MADDAHI, J
    ROZANSKI, A
    BERMAN, D
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 7 (02) : A4 - A4
  • [40] Progression of Coronary Artery Disease in High-Risk Patients Undergoing Renal Transplantation
    Corbett, R.
    Kumar, N.
    Baker, C.
    Moutzouris, D.
    Willicombe, M.
    Galliford, J.
    McLean, A.
    Duncan, N.
    Taube, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15